Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA.
Albert Einstein College of Medicine, Bronx, NY, USA.
Sci Rep. 2023 Nov 11;13(1):19688. doi: 10.1038/s41598-023-46912-4.
We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir/ritonavir; 250 who took nirmatrelvir/ritonavir and 250 who did not. The primary outcome was the development of one or more of eleven prespecified long COVID symptoms, assessed through a structured telephone interview four months after the positive SARS-CoV-2 test. Multivariable logistic regression models controlled for age, sex, race/ethnicity, chronic conditions, and COVID-19 vaccination status. We found that participants who took nirmatrelvir/ritonavir were no less likely to develop long COVID symptoms, compared to those who did not take the medication (44% vs. 49.6%, p = 0.21). Taking nirmatrelvir/ritonavir was associated with a lower odds of two of the eleven long COVID symptoms, brain fog (OR 0.58, 95% CI 0.38-0.88) and chest pain/tightness (OR 0.51, 95% CI 0.28-0.91). Our finding that treatment with nirmatrelvir/ritonavir was not associated with a lower risk of developing long COVID is different from prior studies that obtained data only from electronic medical records.
我们进行了一项回顾性队列研究，以评估奈玛特韦/利托那韦治疗是否与降低长新冠的风险有关。我们招募了 500 名符合奈玛特韦/利托那韦使用条件的确诊 SARS-CoV-2 成年人，其中 250 名接受了奈玛特韦/利托那韦治疗，250 名未接受治疗。主要结局是通过 SARS-CoV-2 阳性检测后四个月的结构化电话访谈评估是否出现十一种预先指定的长新冠症状之一或多种。多变量逻辑回归模型控制了年龄、性别、种族/民族、慢性疾病和 COVID-19 疫苗接种状况。我们发现，与未服用该药的患者相比，服用奈玛特韦/利托那韦的患者发生长新冠症状的可能性没有降低（44%对 49.6%，p=0.21）。服用奈玛特韦/利托那韦与十一种长新冠症状中的两种症状的几率较低相关，包括脑雾（OR 0.58，95%CI 0.38-0.88）和胸痛/胸闷（OR 0.51，95%CI 0.28-0.91）。我们的发现表明，奈玛特韦/利托那韦治疗与降低长新冠风险无关，这与仅从电子病历中获取数据的先前研究不同。
